GEMIN8P4: A Potential Drug Target and Biomarker (G492303)

Target Name: GEMIN8P4

NCBI ID: G492303

GEMIN8P4

Other Name(s): gem nuclear organelle associated protein 8 pseudogene 4 | Gem nuclear organelle associated protein 8 pseudogene 4

GEMIN8P4: A Potential Drug Target and Biomarker

Gemin8p4, also known as gem nuclear organelle associated protein 8 pseudogene 4, is a protein that is expressed in the nuclei of human cells. It plays a critical role in the regulation of cell growth, apoptosis, and nuclear organization, and is therefore considered is a potential drug target. The Gemin8p4 gene is expressed in a variety of cancers, such as lung cancer, liver cancer, breast cancer, etc., and the expression level is closely related to disease severity and prognosis. In addition, Gemin8p4 is also closely related to the progression and treatment response of various malignant tumors. Therefore, Gemin8p4 is considered a promising research object in the field of tumor treatment.

Structure and function of Gemin8p4

Gemin8p4 is a protein with a length of approximately 120 amino acids and is a chromatin structural protein. Its N-terminus contains a nucleolar histocompatibility (NUP) domain, and its N-terminus contains an acetyltransferase active center (5), a unique enzymatic activity that enables Gemin8p4 to engage in the nucleolus RNA processing and modification. The C-terminus of Gemin8p4 contains an acidic domain containing cysteine 鈥嬧??(7). This domain is considered to be the ligand binding site of Gemin8p4 and can interact with other proteins, thereby affecting the function of Gemin8p4.

The role of Gemin8p4 in cell cycle and apoptosis

Gemin8p4 plays an important role in the cell cycle. During G1 phase, Gemin8p4 tightly interacts with histone H3, thereby inhibiting histone dissociation and allowing chromatin to maintain a compact structure in G1 phase. During S phase, the binding of Gemin8p4 to histone H3 is inhibited, resulting in the inability of chromatin to unwind normally, thus interfering with DNA synthesis. During G2 phase, Gemin8p4 promotes the binding of histones to DNA in preparation for chromosome segregation. During M phase, Gemin8p4 is involved in spindle formation and stability, thereby participating in mitosis.

Gemin8p4 is also closely related to apoptosis. Gemin8p4 plays an important role in the apoptosis process. Apoptosis is an important form of cell death that clears damaged cells to maintain tissue and organ homeostasis. Gemin8p4 interacts with apoptosis-related gene (ASF), a key molecule of the apoptosis signaling pathway, during the apoptosis process, thereby participating in the apoptosis process. In addition, Gemin8p4 also interacts with apoptotic enzymes such as Bax and Caspase, thereby promoting apoptosis.

Gemin8p4 potential as a drug target and research methods

Gemin8p4 has attracted widespread research interest as a potential drug target. Since Gemin8p4 is expressed in a variety of cancers, it is regarded as a potential tumor therapeutic target. Currently, some research teams have begun to explore the therapeutic effect of Gemin8p4 as a drug. For example, Gemin8p4 has been used as a drug target to treat lung cancer and conducted phase I clinical trials. In addition, some research teams also explore Gemin8p4 as a biomarker of tumors for early diagnosis and monitoring of treatment effects (18, 19).

Biological effects and clinical applications of Gemin8p4

The potential role of Gemin8p4 in tumor treatment also stems from its biological effects. The tumor suppressor effect of Gemin8p4 is mainly reflected in two aspects: inhibiting the proliferation of tumor cells and promoting the apoptosis of tumor cells. By inhibiting the binding of histones to DNA, Gemin8p4 prevents tumor cells from performing normal DNA replication, thereby inhibiting the proliferation of tumor cells. In addition, Gemin8p4 also regulates

Protein Name: Gem Nuclear Organelle Associated Protein 8 Pseudogene 4

The "GEMIN8P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GEMIN8P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets